Imperial College London
Alternate

Emeritus ProfessorKimFox

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor
 
 
 
//

Contact

 

+44 (0)20 7594 7966kim.fox

 
 
//

Assistant

 

Ms Deborah Curcher +44 (0)20 7594 7966

 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bhatt:2019:10.1016/S0140-6736(19)31887-2,
author = {Bhatt, DL and Steg, PG and Mehta, SR and Leiter, LA and Simon, T and Fox, K and Held, C and Andersson, M and Himmelmann, A and Ridderstråle, W and Chen, J and Song, Y and Diaz, R and Goto, S and James, SK and Ray, KK and Parkhomenko, AN and Kosiborod, MN and McGuire, DK and Harrington, RA and THEMIS, Steering Committee and Investigators},
doi = {10.1016/S0140-6736(19)31887-2},
journal = {The Lancet},
pages = {1169--1180},
title = {Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.},
url = {http://dx.doi.org/10.1016/S0140-6736(19)31887-2},
volume = {394},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. METHODS: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). FINDINGS: Between Feb 17, 2014, and May 24, 2016, 11154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8-3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74-0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, pinteraction=0·16). The proportion of patients with cardiovascular death was similar in b
AU  - Bhatt,DL
AU  - Steg,PG
AU  - Mehta,SR
AU  - Leiter,LA
AU  - Simon,T
AU  - Fox,K
AU  - Held,C
AU  - Andersson,M
AU  - Himmelmann,A
AU  - Ridderstråle,W
AU  - Chen,J
AU  - Song,Y
AU  - Diaz,R
AU  - Goto,S
AU  - James,SK
AU  - Ray,KK
AU  - Parkhomenko,AN
AU  - Kosiborod,MN
AU  - McGuire,DK
AU  - Harrington,RA
AU  - THEMIS,Steering Committee and Investigators
DO  - 10.1016/S0140-6736(19)31887-2
EP  - 1180
PY  - 2019///
SN  - 0140-6736
SP  - 1169
TI  - Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(19)31887-2
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31484629
UR  - https://www.sciencedirect.com/science/article/pii/S0140673619318872?via%3Dihub
UR  - http://hdl.handle.net/10044/1/73260
VL  - 394
ER  -
Download